Jack Schuler Biography and Net Worth

Director of Biodesix

Jack Schuler has served as a Director of the Company since June 2008. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the board from 1995 until Ventana’s acquisition by Roche in 2008. Prior to joining Ventana, Mr. Schuler was President and Chief Operating Officer of Abbott Laboratories, a diversified health care company, which he joined in 1972 and where he held a number of management and marketing positions, also serving as a director from April 1985 to August 1989. Additionally, Mr. Schuler has served as a director of Abbott Laboratories (NYSE:ABT), Medtronic (Lead Director) (NYSE: MDT), Stericyle (Chairman) (NASDAQ: SRCL), Chiron Corporation, and Quidel Corporation (NASDAQ: QDEL), and currently serves on the board of directors of Accelerate Diagnostics (NASDAQ: AXDX). Mr. Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University Graduate School of Business Administration.

What is Jack W. Schuler's net worth?: The estimated net worth of Jack W. Schuler is at least $20.83 million as of November 20th, 2024. Mr. Schuler owns 31,094,935 shares of Biodesix stock worth more than $20,833,606 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Schuler may own. Learn More about Jack W. Schuler's net worth.
How do I contact Jack W. Schuler?: The corporate mailing address for Mr. Schuler and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at chris.brinzey@westwicke.com. Learn More on Jack W. Schuler's contact information.
Has Jack W. Schuler been buying or selling shares of Biodesix?: Jack W. Schuler has not been actively trading shares of Biodesix during the last ninety days. Most recently, on Wednesday, November 20th, Jack W. Schuler bought 200,000 shares of Biodesix stock. The stock was acquired at an average cost of $1.17 per share, with a total value of $234,000.00. Following the completion of the transaction, the director now directly owns 31,094,935 shares of the company's stock, valued at $36,381,073.95. Learn More on Jack W. Schuler's trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, Biodesix insiders bought shares 3 times. They purchased a total of 315,000 shares worth more than $393,500.00. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 139,483 shares worth more than $134,963.43. The most recent insider tranaction occured on February, 11th when CAO Chris Vazquez sold 3,630 shares worth more than $3,339.60. Insiders at Biodesix own 69.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 2/11/2025.

Jack W. Schuler Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2024	Buy	200,000	$1.17	$234,000.00	31,094,935
8/23/2023	Buy	87,500	$1.71	$149,625.00	30,707,722
8/21/2023	Buy	32,556	$1.64	$53,391.84	30,611,915
5/30/2023	Buy	11,849	$1.36	$16,114.64	20,575,061
5/25/2023	Buy	52,508	$1.36	$71,410.88	20,563,212
5/23/2023	Buy	56,782	$1.15	$65,299.30	20,475,396
1/31/2023	Buy	10,000	$2.41	$24,100.00	20,389,189
1/27/2023	Buy	50,000	$2.51	$125,500.00	20,379,189
12/14/2022	Buy	189,675	$1.65	$312,963.75	20,309,189
12/12/2022	Buy	100,000	$1.48	$148,000.00	20,052,112
11/19/2021	Buy	60,000	$6.50	$390,000.00
11/17/2021	Buy	20,000	$6.51	$130,200.00
8/19/2021	Buy	50,000	$7.69	$384,500.00
8/17/2021	Buy	29,440	$7.18	$211,379.20
8/13/2021	Buy	232,000	$7.50	$1,740,000.00

Jack W. Schuler Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $0.67

$0.67

$0.78

50 Day Range

MA: $0.89

$0.67

$1.15

2 Week Range

Now: $0.67

$0.64

$2.04

Volume

157,705 shs

Average Volume

292,441 shs

Market Capitalization

$97.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1